Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management

References

• Bruniera FR, Ferreira FM, Saviolli LR, et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19(4):694–700.
   PubMed Web of Science ®Google Scholar
• Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J. 2010;29(5):462–464. doi:10.1097/INF.0b013e3181db7398
   PubMed Web of Science ®Google Scholar
• Alvarez R, Lopez Cortes LE, Molina J, et al. Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother. 2016;60(5):2601–2609. doi:10.1128/AAC.03147-14
   PubMed Web of Science ®Google Scholar
• da Silva Alves GC, da Silva SD, Frade VP, et al. Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis. Eur J Clin Pharmacol. 2017;73(11):1341–1353. doi:10.1007/s00228-017-2306-3
   PubMed Web of Science ®Google Scholar
• Orr H, Trone D, Elder J, et al. Assessment of initial vancomycin dosing in pediatric oncology patients. Children (Basel). 2017;4(9). doi:10.3390/children4090079
   PubMed Web of Science ®Google Scholar
• Piro CC, Crossno CL, Collier A, et al. Initial vancomycin dosing in pediatric oncology and stem cell transplant patients. J Pediatr Hematol Oncol. 2009;31(1):3–7. doi:10.1097/MPH.0b013e31818b3520
   PubMed Web of Science ®Google Scholar
• Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLOS ONE. 2013;8(10):e77169. doi:10.1371/journal.pone.0077169
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365–380. doi:10.1007/s10156-013-0599-4
   PubMed Web of Science ®Google Scholar
• Patel J, Lucas CJ, Ryan J, et al. Vancomycin therapeutic drug monitoring in paediatrics. J Paediatr Child Health. 2020;56(4):563–570. doi:10.1111/jpc.14683
   PubMed Web of Science ®Google Scholar
• Momper JD, Wagner JA. Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development. Clin Pharmacol Ther. 2014;95(2):138–140. doi:10.1038/clpt.2013.227
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–1153. doi:10.1007/s00134-020-06050-1
   PubMed Web of Science ®Google Scholar
• Monteiro JF, Hahn SR, Goncalves J, et al. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;6(4):e00420. doi:10.1002/prp2.420
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98. doi:10.2146/ajhp080434
   PubMedGoogle Scholar
• Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679–687. doi:10.1093/jac/25.4.679
   PubMed Web of Science ®Google Scholar
• Hammett-Stabler CA, Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem. 1998;44(5):1129–1140. doi:10.1093/clinchem/44.5.1129
   PubMed Web of Science ®Google Scholar
• Lestner JM, Hill LF, Heath PT, et al. Vancomycin toxicity in neonates: a review of the evidence. Curr Opin Infect Dis. 2016;29(3):237–247. doi:10.1097/QCO.0000000000000263
   PubMed Web of Science ®Google Scholar
• Balch AH, Constance JE, Thorell EA, et al. Pediatric vancomycin dosing: trends over time and the impact of therapeutic drug monitoring. J Clin Pharmacol. 2015;55(2):212–220. doi:10.1002/jcph.402
   PubMed Web of Science ®Google Scholar
• Crowley RK, Fitzpatrick F, Solanki D, et al. Vancomycin administration: the impact of multidisciplinary interventions. J Clin Pathol. 2007;60(10):1155–1159. doi:10.1136/jcp.2006.044727
   PubMed Web of Science ®Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239–1276. doi:10.1111/j.1528-1167.2008.01561.x
   PubMed Web of Science ®Google Scholar
• Kang JS, Lee MH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10. doi:10.3904/kjim.2009.24.1.1
   PubMedGoogle Scholar
• Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 2001;52(Suppl. 1):S5–S10. doi:10.1111/j.1365-2125.2001.00770.x
   Google Scholar
• Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit. 1990;12(5):427–433. doi:10.1097/00007691-199009000-00004
   PubMed Web of Science ®Google Scholar
• Maloni TM, Belucci TR, Malagutti SR, et al. Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met. BMC Pediatr. 2019;19(1):240. doi:10.1186/s12887-019-1602-8
   PubMedGoogle Scholar
• Cimolai N. Does oral vancomycin use necessitate therapeutic drug monitoring? Infection. 2020;48(2):173–182. doi:10.1007/s15010-019-01374-7
   PubMed Web of Science ®Google Scholar
• Schesing KB, Chia R, Elwood B, et al. Assessment of patient and provider attitudes towards therapeutic drug monitoring to improve medication adherence in low-income patients with hypertension: a qualitative study. BMJ Open. 2020;10(11):e039940. doi:10.1136/bmjopen-2020-039940
   PubMed Web of Science ®Google Scholar
• Brasso C, Cisotto M, Ghirardini C, et al. Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward. Psychiatry Res. 2021;305:114214. doi:10.1016/j.psychres.2021.114214
   PubMed Web of Science ®Google Scholar
• Hoang J, Dersch-Mills D, Bresee L, et al. Achieving therapeutic vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014;67(6):416–422. doi:10.4212/cjhp.v67i6.1403
   PubMedGoogle Scholar
• Sridharan K, Al-Daylami A, Ajjawi R, et al. Vancomycin use in a paediatric intensive care unit of a Tertiary care hospital. Paediatr Drugs. 2019;21(4):303–312. doi:10.1007/s40272-019-00343-9
   PubMed Web of Science ®Google Scholar
• Hussain K, Salat MS, Rauf S, et al. Practical approaches to improve vancomycin-related patient outcomes in pediatrics- an alternative strategy when AUC/MIC is not feasible. BMC Pharmacol Toxicol. 2022;23(1):64. doi:10.1186/s40360-022-00606-1
   PubMed Web of Science ®Google Scholar
• Abdel Jalil MH, Etaijazeen R, Khaled Abu-Mahfouz F, et al. Vancomycin prescribing and therapeutic drug monitoring: challenges of real clinical practice. PLOS ONE. 2023;18(5):e0285717. doi:10.1371/journal.pone.0285717
   PubMed Web of Science ®Google Scholar
• Firman P, Whitfield K, Tan KS, et al. The impact of an electronic hospital system on therapeutic drug monitoring. J Clin Pharm Ther. 2021;46(6):1613–1621. doi:10.1111/jcpt.13497
   PubMed Web of Science ®Google Scholar
• Van Der Heggen T, Buyle FM, Claus B, et al. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm. 2021;43(5):1394–1403. doi:10.1007/s11096-021-01266-7
   PubMed Web of Science ®Google Scholar
• Carland JE, Stocker SL, Baysari MT, et al. Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. Br J Clin Pharmacol. 2021;87(11):4221–4229. doi:10.1111/bcp.14834
   PubMed Web of Science ®Google Scholar